Oncotarget

Research Papers:

Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21

Tianyang Xu, Wenwei Jiang, Lin Fan, Qiuming Gao and Guodong Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:101406-101417. https://doi.org/10.18632/oncotarget.20738

Metrics: PDF 886 views  |   HTML 1342 views  |   ?  


Abstract

Tianyang Xu1,*, Wenwei Jiang1,*, Lin Fan1, Qiuming Gao1 and Guodong Li1

1Department of Orthopedics, Shanghai Tenth People’s Hospital, Tong Ji University School of Medicine, Shanghai 200072, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Guodong Li, email: litrue2004@163.com

Keywords: osteosarcoma; Xist; proliferation; EZH2; P21

Received: April 25, 2017     Accepted: August 07, 2017     Published: September 08, 2017

ABSTRACT

Recent studies show that lncRNAs involve in the initiation and progression of various cancers including osteosarcoma (OS). IncRNA Xist has been verified as an oncogene in several human cancers, and its abnormal expression was closely associated with tumor initiation and progression. Nevertheless, the role of Xist in OS remains unclear. Here, we revealed the Xist expression level was up-regulated in OS tissues and discovered that Xist knockdown significantly repressed OS cell proliferation. Additionally, mechanistic analysis revealed that Xist can repress P21 expression to regulate OS cell cycle and proliferation by binding to EZH2. Taking all into account, Xist may function in promoting OS cell proliferation and may potentially serve as a novel biomarker and therapeutic target for OS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20738